ArticleInnovation (Cambridge (Mass.))2022
A highly immunogenic live-attenuated vaccine candidate prevents SARS-CoV-2 infection and transmission in hamsters.
Article in Innovation (Cambridge (Mass.)), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- The Vero cell-adapted infectious bronchitis virus strain rHV80 exhibits high immunogenicity and broad tissue tropism.Poultry science · 2026Article
- Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza.Nature communications · 2026Article
- Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV.Science advances · 2025Article
- Intranasal measles virus- and mumps virus-based SARS-CoV-2 vaccine candidates prevent SARS-CoV-2 infection and transmission.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Live attenuated SARS-CoV-2 vaccine OTS-228 demonstrates efficacy, safety, and stability in preclinical model.NPJ vaccines · 2025Article
- Attenuation of a Virulent Porcine Deltacoronavirus Strain DHeB1 via Serial Passage in LLC-PK1 Cells.Viruses · 2025Article
- Article
- A novel pan-epitope based nanovaccine self-assembled with CpG enhances immune responses against flavivirus.Journal of nanobiotechnology · 2024Article
- Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters.Science advances · 2024Article
- Spike N354 glycosylation augments SARS-CoV-2 fitness for human adaptation through structural plasticity.National science review · 2024Article
- Landscape of human organoids: Ideal model in clinics and research.Innovation (Cambridge (Mass.)) · 2024Review
- Fumarprotocetraric acid and geraniin were identified as novel inhibitors of human respiratory syncytial virus infectionFrontiers in cellular and infection microbiology · 2024Article
- A pangolin-origin SARS-CoV-2-related coronavirus: infectivity, pathogenicity, and cross-protection by preexisting immunity.Cell discovery · 2023Article
- Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity.Vaccines · 2023Review
- Contextualizing Wastewater-Based surveillance in the COVID-19 vaccination era.Environment international · 2023Review
- Nanosponges: An overlooked promising strategy to combat SARS-CoV-2.Drug discovery today · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The highly pathogenic and readily transmissible SARS-CoV-2 has caused a global coronavirus pandemic, urgently requiring effective countermeasures against its rapid expansion. All available vaccine platforms are being used to generate safe and effective COVID-19 vaccines. Here, we generated a live-attenuated candidate vaccine strain by serial passaging of a SARS-CoV-2 clinical isolate in Vero cells. Deep sequencing revealed the dynamic adaptation of SARS-CoV-2 in Vero cells, resulting in a stable clone with a deletion of seven amino acids (N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.